Proposed pathophysiological crosstalk between MAFLD and CKD.
<p>This schematic illustrates the proposed pathophysiological crosstalk between Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Chronic Kidney Disease (CKD). <b>Panel A depicts organ-specific mechanisms:</b> in the <i>liver</i>, steatosis (lipid-laden h...
সংরক্ষণ করুন:
| প্রধান লেখক: | |
|---|---|
| অন্যান্য লেখক: | , , , , , |
| প্রকাশিত: |
2025
|
| বিষয়গুলি: | |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
| _version_ | 1849927642875166720 |
|---|---|
| author | Zienab M. Saad (22676502) |
| author2 | Hesham K. H. Keryakos (22676505) Hala A. Hassanin (22676508) Mahmoud M. Higazi (22676511) Manar M. Sayed (22676514) Doaa E. Ismail (22676517) Safaa M. Abdelhalim (21398199) |
| author2_role | author author author author author author |
| author_facet | Zienab M. Saad (22676502) Hesham K. H. Keryakos (22676505) Hala A. Hassanin (22676508) Mahmoud M. Higazi (22676511) Manar M. Sayed (22676514) Doaa E. Ismail (22676517) Safaa M. Abdelhalim (21398199) |
| author_role | author |
| dc.creator.none.fl_str_mv | Zienab M. Saad (22676502) Hesham K. H. Keryakos (22676505) Hala A. Hassanin (22676508) Mahmoud M. Higazi (22676511) Manar M. Sayed (22676514) Doaa E. Ismail (22676517) Safaa M. Abdelhalim (21398199) |
| dc.date.none.fl_str_mv | 2025-11-24T18:27:15Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pone.0336568.g006 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Proposed_pathophysiological_crosstalk_between_MAFLD_and_CKD_/30696948 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Cell Biology Biotechnology Marine Biology Cancer Infectious Diseases Virology shear wave elastography patients remains underexplored mitigate progression risks higher liver stiffness 56 ± 17 43 ± 17 5 ± 28 ></ b >). ></ b >), ></ b >) shared metabolic abnormalities 9 ± 39 invasive fibrosis scores 45 ± 1 2 ± 5 mafld patients also dialysis ckd patients 108 ckd patients metabolic risk factors 5 ± 6 9 ± 1 5 ± 3 6 ± 1 xlink "> mafld xlink "> 5 %, b >< metabolic dysfunction 9 ml risk populations fibrosis severity advanced fibrosis 1 years 2 vs ckd severity 1 vs 6 vs study aimed sectional study participants stratified older age nafld score management strategies lower egfr integrated screening insulin resistance findings highlight diagnostic criteria bidirectional relationship apri score |
| dc.title.none.fl_str_mv | Proposed pathophysiological crosstalk between MAFLD and CKD. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>This schematic illustrates the proposed pathophysiological crosstalk between Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Chronic Kidney Disease (CKD). <b>Panel A depicts organ-specific mechanisms:</b> in the <i>liver</i>, steatosis (lipid-laden hepatocytes) progresses through inflammation (Kupffer cell activation, TNF-α/IL-6 release) to fibrosis (stellate cell activation, collagen deposition); in the <i>kidney</i>, lipotoxicity (podocyte fatty acid influx) leads to podocyte injury (effacement, apoptosis) and glomerulosclerosis (collagen IV accumulation). <b>Panel B highlights systemic mediators</b>: insulin resistance (hyperinsulinemia-driven hepatic gluconeogenesis and renal sodium retention), dyslipidemia (VLDL/ApoB glomerular deposition), and key mediators (fetuin-A, adiponectin deficiency, uric acid-induced NLRP3 activation). Bidirectional interactions amplify organ damage through direct (lipotoxicity, fibrosis) and systemic (metabolic, inflammatory) pathways, suggesting shared therapeutic targets for dual hepatic-renal protection.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_d2dec5b0409e093737087d7185c2b2c1 |
| identifier_str_mv | 10.1371/journal.pone.0336568.g006 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30696948 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Proposed pathophysiological crosstalk between MAFLD and CKD.Zienab M. Saad (22676502)Hesham K. H. Keryakos (22676505)Hala A. Hassanin (22676508)Mahmoud M. Higazi (22676511)Manar M. Sayed (22676514)Doaa E. Ismail (22676517)Safaa M. Abdelhalim (21398199)MedicineCell BiologyBiotechnologyMarine BiologyCancerInfectious DiseasesVirologyshear wave elastographypatients remains underexploredmitigate progression riskshigher liver stiffness56 ± 1743 ± 175 ± 28></ b >).></ b >),></ b >)shared metabolic abnormalities9 ± 39invasive fibrosis scores45 ± 12 ± 5mafld patients alsodialysis ckd patients108 ckd patientsmetabolic risk factors5 ± 69 ± 15 ± 36 ± 1xlink "> mafldxlink ">5 %,b ><metabolic dysfunction9 mlrisk populationsfibrosis severityadvanced fibrosis1 years2 vsckd severity1 vs6 vsstudy aimedsectional studyparticipants stratifiedolder agenafld scoremanagement strategieslower egfrintegrated screeninginsulin resistancefindings highlightdiagnostic criteriabidirectional relationshipapri score<p>This schematic illustrates the proposed pathophysiological crosstalk between Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Chronic Kidney Disease (CKD). <b>Panel A depicts organ-specific mechanisms:</b> in the <i>liver</i>, steatosis (lipid-laden hepatocytes) progresses through inflammation (Kupffer cell activation, TNF-α/IL-6 release) to fibrosis (stellate cell activation, collagen deposition); in the <i>kidney</i>, lipotoxicity (podocyte fatty acid influx) leads to podocyte injury (effacement, apoptosis) and glomerulosclerosis (collagen IV accumulation). <b>Panel B highlights systemic mediators</b>: insulin resistance (hyperinsulinemia-driven hepatic gluconeogenesis and renal sodium retention), dyslipidemia (VLDL/ApoB glomerular deposition), and key mediators (fetuin-A, adiponectin deficiency, uric acid-induced NLRP3 activation). Bidirectional interactions amplify organ damage through direct (lipotoxicity, fibrosis) and systemic (metabolic, inflammatory) pathways, suggesting shared therapeutic targets for dual hepatic-renal protection.</p>2025-11-24T18:27:15ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pone.0336568.g006https://figshare.com/articles/figure/Proposed_pathophysiological_crosstalk_between_MAFLD_and_CKD_/30696948CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/306969482025-11-24T18:27:15Z |
| spellingShingle | Proposed pathophysiological crosstalk between MAFLD and CKD. Zienab M. Saad (22676502) Medicine Cell Biology Biotechnology Marine Biology Cancer Infectious Diseases Virology shear wave elastography patients remains underexplored mitigate progression risks higher liver stiffness 56 ± 17 43 ± 17 5 ± 28 ></ b >). ></ b >), ></ b >) shared metabolic abnormalities 9 ± 39 invasive fibrosis scores 45 ± 1 2 ± 5 mafld patients also dialysis ckd patients 108 ckd patients metabolic risk factors 5 ± 6 9 ± 1 5 ± 3 6 ± 1 xlink "> mafld xlink "> 5 %, b >< metabolic dysfunction 9 ml risk populations fibrosis severity advanced fibrosis 1 years 2 vs ckd severity 1 vs 6 vs study aimed sectional study participants stratified older age nafld score management strategies lower egfr integrated screening insulin resistance findings highlight diagnostic criteria bidirectional relationship apri score |
| status_str | publishedVersion |
| title | Proposed pathophysiological crosstalk between MAFLD and CKD. |
| title_full | Proposed pathophysiological crosstalk between MAFLD and CKD. |
| title_fullStr | Proposed pathophysiological crosstalk between MAFLD and CKD. |
| title_full_unstemmed | Proposed pathophysiological crosstalk between MAFLD and CKD. |
| title_short | Proposed pathophysiological crosstalk between MAFLD and CKD. |
| title_sort | Proposed pathophysiological crosstalk between MAFLD and CKD. |
| topic | Medicine Cell Biology Biotechnology Marine Biology Cancer Infectious Diseases Virology shear wave elastography patients remains underexplored mitigate progression risks higher liver stiffness 56 ± 17 43 ± 17 5 ± 28 ></ b >). ></ b >), ></ b >) shared metabolic abnormalities 9 ± 39 invasive fibrosis scores 45 ± 1 2 ± 5 mafld patients also dialysis ckd patients 108 ckd patients metabolic risk factors 5 ± 6 9 ± 1 5 ± 3 6 ± 1 xlink "> mafld xlink "> 5 %, b >< metabolic dysfunction 9 ml risk populations fibrosis severity advanced fibrosis 1 years 2 vs ckd severity 1 vs 6 vs study aimed sectional study participants stratified older age nafld score management strategies lower egfr integrated screening insulin resistance findings highlight diagnostic criteria bidirectional relationship apri score |